Angelini Pharma completes $4.1bn Catalyst Pharmaceuticals buyout
Angelini Pharma has completed its acquisition of Catalyst Pharmaceuticals, paying USD 31.50 per share in cash and valuing the Florida-based rare-disease specialist at approximately USD 4.1 billion (around EUR 3.5 billion). Catalyst's common stock has ceased trading on the Nasdaq Global Market following the closing, and the company now operates as a wholly owned subsidiary within a newly created Global Rare Disease Business Unit.
The deal is the largest single transaction in Angelini Industries' history and marks a significant geographical pivot for the Rome-headquartered group, which until now has drawn the bulk of its commercial revenue from European markets. Catalyst brings an established US commercial infrastructure, a product portfolio focused on rare neurological conditions including Lambert-Eaton myasthenic syndrome, and what the company describes as an epilepsy and brain health franchise complementary to Angelini Pharma's existing European portfolio.
Financing and investors
The transaction was structured with two sizeable equity injections alongside debt financing from a consortium of 14 banks. Blackstone will invest EUR 1 billion in preferred equity, subject to customary regulatory clearances, while CDP Equity, the investment arm of Italy's state-backed Cassa Depositi e Prestiti, has approved a separate EUR 1 billion capital increase in exchange for a 23.5 per cent stake in Angelini Pharma's common equity. BNP Paribas acted as sole global coordinator and underwriter for the debt financing package.
Sergio Marullo di Condojanni, chief executive of Angelini Pharma, said the completion of the deal gives the group "the scale needed to build a next-generation therapeutic platform in Brain Health and Rare Disease, while continuing to strengthen our core business in Europe." Rich Daly, who previously led Catalyst and will head the new Global Rare Disease Business Unit, described the combination as an opportunity to "create an impressive new global scale" for patients living with rare diseases.
Market context and competitive read-across
The rare neurological disease space has attracted sustained strategic interest from mid-sized European pharmaceuticals companies seeking to establish or enlarge a US commercial footprint without the cost and timeline risk of building one from scratch. Acquiring an already-listed US operator with an approved product, a patient services infrastructure and a recognised commercial team materially compresses that timeline, which explains the premium Angelini was prepared to pay.
CDP Equity's involvement is notable beyond its capital contribution. The Italian state-development investor has signalled a deliberate strategy of backing domestic champions in high-value life sciences sectors, positioning Italy as a production and research hub rather than ceding ground to purely financial acquirers. CDP Equity chief executive Fabio Barchiesi described the investment as consistent with the organisation's strategic plan to support "the competitiveness, strategic autonomy and economic security" of Italy's industrial sector, language that carries a political economy dimension worth watching as the group integrates its US operations.
For Blackstone Life Sciences, the preferred equity position follows a pattern the firm has established of providing bespoke capital structures to biopharma companies at inflection points, rather than straightforward buyout transactions. The structure gives Blackstone downside protection through the preferred instrument while retaining upside exposure to Angelini Pharma's growth trajectory across both the rare-disease and broader brain health segments.
The near-term milestones for the combined group will include completing the commercial and operational integration of Catalyst's US business, presenting a consolidated pipeline across brain health and rare diseases, and demonstrating revenue growth in the US market to justify the acquisition premium to CDP Equity's stakeholders.